Soblidotin (BioDeep_00000837805)

   


代谢物信息卡片


Soblidotin

化学式: C39H67N5O6 (701.5091081999999)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NCCC2=CC=CC=C2)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C
InChI: InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

Soblidotin



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Akihito Yokosuka, Mitsue Haraguchi, Takeo Usui, Sayaka Kazami, Hiroyuki Osada, Takao Yamori, Yoshihiro Mimaki. Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells. Bioorganic & medicinal chemistry letters. 2007 Jun; 17(11):3091-4. doi: 10.1016/j.bmcl.2007.03.044. [PMID: 17428663]
  • Tsugitaka Natsume, Junichi Watanabe, Kenji Ogawa, Kazuhiko Yasumura, Motohiro Kobayashi. Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy. Cancer science. 2007 Apr; 98(4):598-604. doi: 10.1111/j.1349-7006.2007.00418.x. [PMID: 17284247]
  • A Greystoke, S Blagden, A L Thomas, E Scott, G Attard, R Molife, L Vidal, S Pacey, D Sarkar, A Jenner, J S De-Bono, W Steward. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Aug; 17(8):1313-9. doi: 10.1093/annonc/mdl097. [PMID: 16728482]
  • May S Kung Sutherland, Russell J Sanderson, Kristine A Gordon, Jamie Andreyka, Charles G Cerveny, Changpu Yu, Timothy S Lewis, Damon L Meyer, Roger F Zabinski, Svetlana O Doronina, Peter D Senter, Che-Leung Law, Alan F Wahl. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. The Journal of biological chemistry. 2006 Apr; 281(15):10540-7. doi: 10.1074/jbc.m510026200. [PMID: 16484228]
  • Che-Leung Law, Kristine A Gordon, Brian E Toki, Andrew K Yamane, Michelle A Hering, Charles G Cerveny, Joseph M Petroziello, Maureen C Ryan, Leia Smith, Ronald Simon, Guido Sauter, Ezogelin Oflazoglu, Svetlana O Doronina, Damon L Meyer, Joseph A Francisco, Paul Carter, Peter D Senter, John A Copland, Christopher G Wood, Alan F Wahl. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer research. 2006 Feb; 66(4):2328-37. doi: 10.1158/0008-5472.can-05-2883. [PMID: 16489038]
  • Maja J A de Jonge, Ate van der Gaast, André S T Planting, Leny van Doorn, Aletta Lems, Inge Boot, Jantien Wanders, Masahiko Satomi, Jaap Verweij. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May; 11(10):3806-13. doi: 10.1158/1078-0432.ccr-04-1937. [PMID: 15897580]
  • Daniel E H Afar, Vinay Bhaskar, Eric Ibsen, Danna Breinberg, Susan M Henshall, James G Kench, Marija Drobnjak, Rick Powers, Melanie Wong, Ferdinand Evangelista, Chris O'Hara, David Powers, Robert B DuBridge, Ingrid Caras, Ruth Winter, Terri Anderson, Nanette Solvason, Phillip D Stricker, Carlos Cordon-Cardo, Howard I Scher, John J Grygiel, Robert L Sutherland, Richard Murray, Vanitha Ramakrishnan, Debbie A Law. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Molecular cancer therapeutics. 2004 Aug; 3(8):921-32. doi: NULL. [PMID: 15299075]
  • Svetlana O Doronina, Brian E Toki, Michael Y Torgov, Brian A Mendelsohn, Charles G Cerveny, Dana F Chace, Ron L DeBlanc, R Patrick Gearing, Tim D Bovee, Clay B Siegall, Joseph A Francisco, Alan F Wahl, Damon L Meyer, Peter D Senter. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature biotechnology. 2003 Jul; 21(7):778-84. doi: 10.1038/nbt832. [PMID: 12778055]
  • T Woyke, G R Pettit, G Winkelmann, R K Pettit. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE. Antimicrobial agents and chemotherapy. 2001 Dec; 45(12):3580-4. doi: 10.1128/aac.45.12.3580-3584.2001. [PMID: 11709343]
  • H Ochiai, H Mori, H Murata, T Seki, K Araki, Y Kawabe, K Miyazaki, K Tsukamoto, S Iwamura. Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography-mass spectrometry. Journal of chromatography. B, Biomedical sciences and applications. 2001 Oct; 762(2):155-63. doi: 10.1016/s0378-4347(01)00360-7. [PMID: 11678375]
  • T Natsume, M Kobayashi, S Fujimoto. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer. 2001 Jul; 92(2):386-94. doi: 10.1002/1097-0142(20010715)92:2<386::aid-cncr1334>3.0.co;2-v. [PMID: 11466694]